SCOPUS 정보 검색 플랫폼

Volumn 31, Issue 8, 2009, Pages 1882-1884

Letter to the editor

(6) Daley Yates, Peter T a Parkins, David A a Thomas, Marian J a Gillett, Benjamin a House, Karen W b Ortega, Hector G b

a GLAXOSMITHKLINE (United Kingdom)

b GLAXOSMITHKLINE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUTICASONE PROPIONATE;

AIRWAY RESISTANCE; BIOEQUIVALENCE; DRUG EFFICACY; DRUG SAFETY; FLOW RATE; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; LETTER; PARTICLE SIZE; PATIENT SAFETY; PRACTICE GUIDELINE; RISK FACTOR; SAMPLE SIZE;

EID: 72549098471 PISSN: 01492918 EISSN: 1879114X Source Type: Journal
DOI: 10.1016/S0149-2918(09)00315-4 Document Type: Letter

Times cited : (2)

References (5)

1
- 62149094354
- Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 μg and fluticasone propionate 250 μg: Implications for establishing bioequivalence of inhaled products
- Daley-Yates P.T., Parkins D.A., Thomas M.J., et al. Pharmacokinetic, pharmacodynamic, efficacy, and safety data from two randomized, double-blind studies in patients with asthma and an in vitro study comparing two dry-powder inhalers delivering a combination of salmeterol 50 μg and fluticasone propionate 250 μg: Implications for establishing bioequivalence of inhaled products. Clin Ther. 31 (2009) 370-385
- (2009) Clin Ther. , vol.31 , pp. 370-385
- Daley-Yates, P.T.¹ Parkins, D.A.² Thomas, M.J.³

2
- 72549095454
- European Medicines Agency Accessed May 8, 2009
- European Medicines Agency. Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. http://www.emea.europa.eu/pdfs/human/ewp/415100enfin.pdf Accessed May 8, 2009
- Guideline on the requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD) in adults and for use in the treatment of asthma in children and adolescents

3
- 33846652603
- Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols, Part 1: Background for a statistical method
- Adams W.P., Christopher D., Lee D.S., et al. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols, Part 1: Background for a statistical method. AAPS PharmSciTech. 8 (2007) 4
- (2007) AAPS PharmSciTech. , vol.8 , pp. 4
- Adams, W.P.¹ Christopher, D.² Lee, D.S.³

4
- 33846659148
- Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols: Part 2-evaluation of a method for determining equivalence
- Christopher D., Adams W.P., Lee D.S., et al. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols: Part 2-evaluation of a method for determining equivalence. AAPS PharmSciTech. 8 (2007) 5
- (2007) AAPS PharmSciTech. , vol.8 , pp. 5
- Christopher, D.¹ Adams, W.P.² Lee, D.S.³

5
- 36949015610
- Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols: Part 3. Final report on a statistical procedure for determining equivalence
- Christopher D., Adams W., Amann A., et al. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols: Part 3. Final report on a statistical procedure for determining equivalence. AAPS PharmSciTech. 8 (2007) E90
- (2007) AAPS PharmSciTech. , vol.8
- Christopher, D.¹ Adams, W.² Amann, A.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.